Prosecution Insights
Last updated: August 18, 2026

Examiner: CLOW, LORI A

Tech Center 3700 • Art Units: 1631 1671 1687 3781

This examiner grants 64% of resolved cases

Performance Statistics

64.0%
Allow Rate
-6.0% vs TC avg
739
Total Applications
+28.6%
Interview Lift
1543
Avg Prosecution Days
Based on 712 resolved cases, 2023–2026

Rejection Statute Breakdown

26.0%
§101 Eligibility
11.8%
§102 Novelty
27.8%
§103 Obviousness
23.2%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
18041362 MONITORING AND CONTROLLING BACTERIOPHAGE PRESSURE Non-Final OA DSM IP ASSETS B.V.
19342186 MODEL-IN-THE-LOOP SYNTHETIC BIOLOGY Non-Final OA X Development LLC
17574915 DISEASE REPRESENTATION AND CLASSIFICATION WITH MACHINE LEARNING Final Rejection X Development LLC
17406948 IDENTIFICATION AND USE OF CIRCULATING NUCLEIC ACID TUMOR MARKERS Final Rejection The Board of Trustees of the Leland Stanford Junior University
17937259 IDENTIFYING PRESENCE AND COMPOSITION OF CELL-FREE NUCLEIC ACIDS Non-Final OA Regents of the University of Minnesota
17371850 IN VITRO EVALUATION METHOD FOR RISK OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE ASSOCIATED WITH SMOKING OR INHALATION Final Rejection Japan Tobacco Inc.
17821916 UTILIZING DEEP REINFORCEMENT LEARNING FOR DISCOVERING NEW COMPOUNDS Non-Final OA Accenture Global Solutions Limited
17686953 Biomarkers and Methods for Measuring and Monitoring Inflammatory Disease Activity Final Rejection Laboratory Corporation of America Holdings
18168870 SYSTEMS AND METHODS FOR PATIENT IMAGE PROCESSING TO EVALUATE TISSUE FUNCTION Non-Final OA HeartFlow, Inc.
17399704 SYSTEMS AND METHODS FOR PATIENT-SPECIFIC IMAGING AND MODELING OF DRUG DELIVERY Non-Final OA HeartFlow, Inc.

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month